Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30668845 | 1.00 | CYP11B1 (0.37) | CYP11B1CYP11B2MEN1SLC22A1KCNN4 | |
| SCHEMBL21820970 | 0.79 | CYP11B1 (0.34) | CYP11B1CYP11B2 | |
| SCHEMBL9705370 | 0.72 | PI4KA (0.37) | CYP11B1CYP11B2EGFRADORA2A | |
| SCHEMBL6699970 | 0.72 | PI4KA (0.59) | EGFRLMNAADORA2AADORA1SMN1; SMN2 | |
| SCHEMBL13012219 | 0.70 | TYMP (0.45) | MEN1LMNATP53ADORA3MAPT | |
| SCHEMBL30582407 | 0.69 | NR3C1 (0.32) | CYP11B1CYP11B2MEN1SLC22A1KCNN4 | |
| SCHEMBL285259 | 0.68 | CYP17A1 (0.35) | CYP11B1CYP11B2KCNN4TP53CYP17A1 | |
| SCHEMBL15921702 | 0.68 | P2RX7 (0.46) | CYP11B1CYP11B2MEN1SLC22A1KCNN4 | |
| SCHEMBL16247699 | 0.67 | ADORA1 (0.44) | CYP1A2GLACYP3A4CYP2D6TSHR | |
| SCHEMBL643809 | 0.67 | CYP11B1 (0.37) | CYP11B1CYP11B2MEN1SLC22A1KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466884-A | Heterocyclic compounds or salts thereof as ATR kinase inhibitors, pharmaceutical compositions containing same and uses thereof | 德州大学系统董事会 | 2024-01-30 | — | — | CN | disclosed |
| EP-3651768-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-111867590-B | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2023-11-17 | — | — | CN | disclosed |
| US-11434233-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210047311-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-20210047311-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| CN-111867590-A | Heterocyclic inhibitors of ATR kinase | 德州大学系统董事会 | 2020-10-30 | — | — | CN | disclosed |
| US-10800769-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800769-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-13 | — | — | US | disclosed |
| US-20200102296-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | SHANGPHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-20200102296-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | SHANGPHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-10392376-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392376-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-27 | — | — | US | disclosed |
| WO-2019014618-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800769-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | CYP11B1 2795/4885CYP11B2 3040/4885MEN1 2344/4885 |
| US-10392376-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | CYP11B1 2795/4885CYP11B2 3040/4885MEN1 2344/4885 |
| US-11434233-B2 | Heterocyclic inhibitors of ATR kinase | ATR, CHEK1, CHEK2 | CYP11B1 2795/4885CYP11B2 3040/4885MEN1 2344/4885 |
| US-20200102296-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | CYP11B1 2795/4885CYP11B2 3040/4885MEN1 2344/4885 |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | CYP11B1 2795/4885CYP11B2 3040/4885MEN1 2344/4885 |
| US-20210047311-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | CYP11B1 2795/4885CYP11B2 3040/4885MEN1 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.